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BACKGROUND
Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the 
pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of 
GABA type A receptors, is effective and safe for the treatment of major depressive dis-
order is unknown.
METHODS
In this double-blind, phase 2 trial, we enrolled patients with major depression and ran-
domly assigned them in a 1:1 ratio to receive 30 mg of SAGE-217 or placebo once daily. 
The primary end point was the change from baseline to day 15 in the score on the 17-item 
Hamilton Depression Rating Scale (HAM-D; scores range from 0 to 52, with higher scores 
indicating more severe depression). Secondary efficacy end points, which were assessed 
on days 2 through 8 and on days 15, 21, 28, 35, and 42, included changes from baseline 
in scores on additional depression and anxiety scales, a reduction from baseline of more 
than 50% in the HAM-D score, a HAM-D score of 7 or lower, and a Clinical Global Im-
pression of Improvement score of 1 (very much improved) or 2 (much improved) (on a 
scale of 1 to 7, with a score of 7 indicating that symptoms are very much worse).
RESULTS
A total of 89 patients underwent randomization: 45 patients were assigned to the SAGE-
217 group, and 44 to the placebo group. The mean baseline HAM-D score was 25.2 in 
the SAGE-217 group and 25.7 in the placebo group. The least-squares mean (±SE) change 
in the HAM-D score from baseline to day 15 was −17.4±1.3 points in the SAGE-217 group 
and −10.3±1.3 points in the placebo group (least-squares mean difference in change, 
−7.0 points; 95% confidence interval, −10.2 to −3.9; P<0.001). The differences in second-
ary end points were generally in the same direction as those of the primary end point. 
There were no serious adverse events. The most common adverse events in the SAGE-217 
group were headache, dizziness, nausea, and somnolence.
CONCLUSIONS
Administration of SAGE-217 daily for 14 days resulted in a reduction in depressive symp-
toms at day 15. Adverse events were more common in the SAGE-217 group than in the 
placebo group. Further trials are needed to determine the durability and safety of SAGE-
217 in major depressive disorder and to compare SAGE-217 with available treatments. 
(Funded by Sage Therapeutics; ClinicalTrials.gov number, NCT03000530.)
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Antidepressants that primarily en-hance monoaminergic neurotransmission involving serotonin or norepinephrine are 
used in the treatment of major depressive dis-
order, and their clinical effects are generally 
evident in 4 to 8 weeks.1-3 One hypothesis for the 
mechanism of depression implicates deficits in 
γ-aminobutyric acid (GABA) and downstream 
alterations in monoaminergic neurotransmis-
sion.4 This hypothesis is supported by evidence 
that reduced GABA levels have been observed in 
plasma, cerebrospinal fluid,5-7 and cortical brain 
tissues8-11 of patients with depression. In addi-
tion, reduced expression of GABA-synthesizing 
enzymes in the brain tissue of persons who 
have died by suicide,12,13 a reduced number of 
GABAergic interneurons in the brain tissue of 
patients with depression,14 and reduced mRNA 
for GABA type A (GABAA) α4 and δ subunits 
(which encode extrasynaptic GABAA receptors) in 
the brain tissue of persons with depression who 
have died by suicide15 have been observed.
Neurosteroids, which are synthesized from 
cholesterol in the brain, are potent modulators 
of GABA and glutamate.16 Despite their steroid 
structure, their target activity and pharmaco-
logic characteristics are distinct from those of 
glucocorticoids and differ in both genomic and 
nongenomic effects.17,18 Preclinical studies have 
shown that the naturally occurring neurosteroid 
allopregnanolone is a positive allosteric modula-
tor of synaptic and extrasynaptic GABAA recep-
tors that affects both phasic and tonic inhibition 
of neurons.16,19 In rodents, allopregnanolone is 
synthesized locally in the brain in response to 
acute stressors.19-21 With experimental chronic 
stress, however, levels of allopregnanolone in 
the brain decrease, and behavioral changes nor-
malize after treatments that increase allopreg-
nanolone levels.19,22,23
Reduced levels of allopregnanolone in the 
cerebrospinal f luid normalize after successful 
treatment of depression with antidepressants.24 
Placebo-controlled trials in patients with post-
partum depression have shown efficacy of a 60-
hour infusion of brexanolone, an intravenous 
formulation of allopregnanolone, which supports 
the hypothesis of GABAergic dysfunction in that 
form of depression.25,26
SAGE-217 — an oral, synthetic neurosteroid 
and positive allosteric modulator of GABAA recep-
tors — has shown anticonvulsant, anxiolytic, 
and sedative properties in studies of seizure in 
rodent models.27-29 A functional assay measuring 
both agonistic and antagonistic effects of SAGE-
217 has indicated no activity on a panel of 22 
nuclear hormone receptors.30
Studies of single ascending and multiple as-
cending doses in healthy volunteers have shown 
that SAGE-217 has a plasma half-life of 16 to 23 
hours, which is compatible with once-daily dos-
ing; sedation is the most common adverse 
event.31,32 We previously conducted an open-label, 
uncontrolled pilot trial of SAGE-217 involving 
patients with major depressive disorder who were 
treated for 14 days. The results suggested that 
SAGE-217, like intravenous brexanolone (with 
which it shares a similar molecular pharmacol-
ogy profile), may be associated with a rapid on-
set of action.33 Here we report the results of a 
randomized, double-blind, placebo-controlled trial 
of SAGE-217 in patients with major depressive 
disorder. The protocol of the current trial (which 
also contains the protocol of the open-label pilot 
trial) and the statistical analysis plan are avail-
able with the full text of this article at NEJM.org. 
The results of the pilot trial are provided in the 
Supplementary Appendix, available at NEJM.org. 
The pilot trial and the current placebo-controlled 
trial recruited different patients.
Me thods
Trial Design and Oversight
This phase 2 trial was conducted at eight sites in 
the United States from April 2017 through Octo-
ber 2017. A list of sites and principal investiga-
tors is provided in the Supplementary Appendix. 
Approval was obtained from the institutional 
review board at each site, and written informed 
consent was obtained from each patient. Sage 
Therapeutics designed the trial, provided the 
SAGE-217 and placebo, collected and analyzed 
the data, and paid for professional writing as-
sistance. The qualification process for end-point 
raters and administration of assessments were 
overseen by Bracket Global (Wayne, PA) (details 
are provided in the Supplementary Appendix). 
Confidentiality agreements exist between the 
authors and Sage Therapeutics. All the authors 
vouch for the accuracy and completeness of the 
data and analyses, the fidelity of the trial to the 
protocol, and the completeness of reporting of 
adverse events.
A Quick Take is 
available at 
NEJM.org 
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We recruited patients from outpatient clinics 
and by using advertising materials approved by 
the institutional review boards. Patients were 
admitted as inpatients for the first week of the 
trial to facilitate daily assessments. Randomiza-
tion was performed with the use of interactive-
response technology created by 4G Clinical 
(Wellesley, MA). Patients were assigned, in a 1:1 
ratio, to receive either SAGE-217 (30 mg) or pla-
cebo. SAGE-217 or placebo was administered at 
8 p.m. with food on days 1 through 14. Patients 
who had adverse effects or reported sedation 
with the 30-mg dose could receive 20 mg daily; 
patients who had adverse effects or reported 
sedation with the 20-mg dose could be with-
drawn from the trial. Initiation of new antide-
pressants was not allowed for the duration of 
the 14-day treatment period. During the 4 weeks 
after the treatment period, primary psychiatrists 
or investigators could adjust the dose of existing 
antidepressants or prescribe new antidepressants 
for patients as appropriate. No formal psycho-
therapy was used as part of the trial, except in 
the case of three patients (two patients in the 
SAGE-217 group and one patient in the placebo 
group) who had been receiving psychotherapy 
for longer than 1 year at trial entry and contin-
ued this treatment throughout the trial. Patients 
had to discontinue the trial regimen if they had 
a new condition that would have met exclusion 
criteria, was clinically relevant, or was unsafe 
(i.e., treatment for the condition was no longer 
associated with a favorable risk–benefit ratio as 
judged by the investigator or sponsor), or if they 
had unacceptable adverse events.
Trial Participants
The trial population included men and women, 
18 to 65 years of age, who had received a diag-
nosis of major depressive disorder and had a 
score on the 17-item Hamilton Depression Rating 
Scale (HAM-D) of 22 or higher, which corre-
sponds to moderate-to-severe depression (scores 
range from 0 to 52, with higher scores indicat-
ing more severe depression).34 The diagnosis of 
depression was made with the use of the Struc-
tured Clinical Interview for Diagnostic and Statisti-
cal Manual of Mental Disorders, fifth edition, Axis I 
disorders.35
Patients were eligible to participate if they 
had been receiving stable doses of antidepres-
sants for at least 30 days or if they were not 
taking antidepressants. Key exclusion criteria 
were a history of a suicide attempt, a history of 
treatment-resistant depression, a recent history 
or current clinically significant manifestations of 
other acute or chronic medical conditions, a pos-
itive pregnancy test, a history of seizures, and 
a history of bipolar disorder, schizophrenia, or 
schizoaffective disorder. A full list of inclusion 
and exclusion criteria is provided in the Supple-
mentary Appendix.
End Points
The primary end point was the change in the 
HAM-D score from baseline to day 15. The sec-
ondary end points, which were assessed on days 
2 through 8 and on days 15, 21, 28, 35, and 42, 
included the change from baseline in HAM-D 
score; a reduction of more than 50% from base-
line in the HAM-D score; a HAM-D score of 7 or 
lower; the change from baseline in the score on 
the Montgomery–Åsberg Depression Rating Scale 
(MADRS; scores range from 0 to 60, with higher 
scores indicating more severe depression); the 
change from baseline in the score on Bech-6 
(a subscale of HAM-D that assesses the overall 
severity of depression on the basis of ratings in 
six categories [depressed mood, feelings of guilt, 
work and activities, psychomotor retardation, 
psychic anxiety, and general somatic symptoms]; 
scores range from 0 to 100, with higher scores 
indicating more severe depression)36; the change 
from baseline in the score on the Hamilton 
Anxiety Rating Scale (HAM-A; scores range from 
0 to 56, with higher scores indicating more se-
vere anxiety); and a score on the Clinical Global 
Impression of Improvement (CGI-I) scale of 1 
(very much improved) or 2 (much improved) 
(scores range from 1 to 7, with a score of 7 in-
dicating that symptoms are very much worse).37
Safety was assessed on the basis of the fre-
quency and severity of adverse events, vital signs, 
changes in clinical laboratory measurements, 
physical examinations, electrocardiography, the 
Stanford Sleepiness Scale, and assessment of 
suicidal ideation and behavior with the use of 
the Columbia Suicide Severity Rating Scale. Ad-
verse events during the treatment period were 
defined as any adverse events or any worsening 
of a preexisting medical condition that occurred 
from the time of administration of the first dose 
of SAGE-217 or placebo until 7 days after the 
last dose.
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Statistical Analysis
Analyses were performed according to the inten-
tion-to-treat principle and included all patients 
who underwent randomization. Continuous vari-
ables are reported as means and standard devia-
tions, and categorical variables as numbers and 
percentages. The least-squares mean changes 
from baseline in HAM-D, Bech-6, MADRS, and 
HAM-A scores were analyzed with the use of 
mixed-effects models for repeated measures, with 
treatment, visit, and treatment-by-visit interaction 
as fixed effects and with adjustment for baseline 
score, use of antidepressants, and trial site. Cate-
gorical measures (i.e., >50% reduction in HAM-D 
score from baseline, HAM-D score ≤7, and CGI-I 
score of 1 or 2) were analyzed with the use of 
a generalized estimating equation model, with 
treatment, visit, and treatment-by-visit interaction 
as fixed effects and with adjustment for baseline 
score, use of antidepressants, and trial site. Sta-
tistical analyses were performed with the use of 
SAS software, version 9.3 (SAS Institute). There 
was no plan for imputation of missing data, but 
sensitivity analyses were performed to assess the 
effect of missing data. The statistical analysis 
plan did not include a provision for correction 
for multiplicity when the analyses of secondary 
end points were performed. Therefore, the results 
Figure 1. Screening, Randomization, and Follow-up.
89 Were enrolled and underwent
randomization
169 Patients were assessed for eligibility
59 Were ineligible
21 Did not undergo randomization
8 Were excluded by the sponsor
5 Had other reason
4 Withdrew
4 Were lost to follow-up
45 Were assigned to and received
SAGE-217
44 Were assigned to and received
placebo
41 Completed the trial
4 Discontinued the trial
2 Had adverse event
1 Was lost to follow-up
1 Withdrew
39 Completed the trial
5 Discontinued the trial
3 Were lost to follow-up
2 Withdrew
45 Were included in the safety
and the efficacy analyses
44 Were included in the safety
and the efficacy analyses
Characteristic SAGE-217 Group (N = 45) Placebo Group (N = 44)
Age — yr 49.1±13.6 38.3±12.2
Male sex — no. (%) 20 (44) 14 (32)
Race or ethnic group — no. (%)†
American Indian or Alaska Native 0 0
Asian 1 (2) 0
Black 36 (80) 28 (64)
Native Hawaiian or Pacific Islander 0 0
White  7 (16) 16 (36)
Other 1 (2) 0
Body-mass index‡ 30.0±6.3 29.9±5.2
Baseline HAM-D score§ 25.2±2.6 25.7±2.4
Use of antidepressants at baseline — no. (%) 12 (27) 10 (23)
Median duration of depression (IQR) — days 97 (63–161) 146 (86–204)
*  Plus–minus values are means ±SD. IQR denotes interquartile range.
†  Race was reported by the patients.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Scores on the 17-item Hamilton Depression Rating Scale (HAM-D) range from 0 to 52, with higher scores indicating more 
severe depression.
Table 1. Characteristics of the Patients.*
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are reported as point estimates and unadjusted 
95% confidence intervals and should not be used 
to infer treatment effects.
R esult s
Patient Characteristics
A total of 169 patients were screened, of whom 
89 were enrolled and underwent randomization. 
Patients were assigned in a 1:1 ratio to receive 
SAGE-217 (45 patients) or placebo (44 patients) 
(Fig. 1). Demographic characteristics were simi-
lar in the two groups except that patients in the 
SAGE-217 group were older than those in the 
placebo group (mean age, 49 years vs. 38 years), 
there were fewer women in the SAGE-217 group 
than in the placebo group (56% vs. 68%), and 
there were more black patients in the SAGE-217 
group than in the placebo group (80% vs. 64%) 
(Table 1). Most patients (96% in the SAGE-217 
group and 91% in the placebo group) reported 
previous depressive episodes. The percentage of 
patients who were receiving antidepressants at 
baseline was 27% in the SAGE-217 group and 
23% in the placebo group, and the duration of 
this treatment before the patients entered the 
trial was 2 months to more than 48 months 
(Table S3 in the Supplementary Appendix). In 
the SAGE-217 group, 2 patients discontinued the 
trial drug because of adverse events (1 patient 
after day 6 and 1 patient after day 10). One patient 
was lost to follow-up after 9 days, and 1 patient 
withdrew consent after 10 days (neither of these 
patients had adverse events). In the placebo group, 
3 patients were lost to follow-up during the fol-
low-up period, and 2 patients withdrew from the 
trial (1 patient after 5 days and 1 patient after 
6 days).
Efficacy
The mean HAM-D score at baseline was 25.2 in 
the SAGE-217 group and 25.7 in the placebo 
group. On day 15, the least-squares mean change 
from baseline in HAM-D score was −17.4±1.3 
points in the SAGE-217 group and −10.3±1.3 
points in the placebo group (least-squares mean 
difference in change, −7.0; 95% confidence inter-
val [CI], −10.2 to −3.9; P<0.001) (Table 2). Results 
of the sensitivity analyses for missing data that 
used multiple imputation or the last-observation-
End Point
SAGE-217 Group 
(N = 45)
Placebo Group 
(N = 44) Difference Odds Ratio 95% CI P Value
Primary end point: change from baseline 
in HAM-D score†
−17.4±1.3 −10.3±1.3 −7.0±1.6 −10.2 to −3.9 <0.001
Secondary end points
Reduction of >50% from baseline in 
HAM-D score — % of patients
79 41 9.6 2.9 to 31.6
HAM-D score ≤7 — % of patients 64 26 5.3 2.1 to 13.3
Change from baseline in Bech-6 score‡ −40.7±3.3 −25.7±3.4 −15.1±4.1 −23.3 to −6.8
Change from baseline in MADRS 
score§
−22.5±1.9 −15.0±1.9 −7.6±2.4 −12.3 to −2.8
Change from baseline in HAM-A 
score¶
−13.2±1.1 −8.6±1.1 −4.6±1.3 −7.3 to −2.0
CGI-I score of 1 or 2 — % of patients‖ 79 45 8.6 2.5 to 29.5
*  Plus–minus values are least-squares means ±SE. The least-squares mean changes from baseline in the scores on the HAM-D, Bech-6, 
Montgomery–Åsberg Depression Rating Scale (MADRS), and Hamilton Anxiety Rating Scale (HAM-A) were calculated with the use of a 
mixed-effects model for repeated measures. The least-squares mean differences are for SAGE-217 minus placebo. The listed odds ratios 
were calculated with the use of a generalized estimating equation model, with treatment, visit, and treatment-by-visit interaction as fixed 
 effects and with adjustment for baseline score, use of antidepressants, and trial site. The 95% confidence intervals for secondary end points 
have not been adjusted for multiple testing. There was no plan for imputation of missing data for primary or secondary end points.
†  Data are missing for 3 patients in the SAGE-217 group and 2 patients in the placebo group.
‡  Scores on the Bech-6 subscale of the HAM-D range from 0 to 100, with higher values indicating more severe depression.
§  MADRS scores range from 0 to 60, with higher scores indicating more severe depression.
¶  HAM-A scores range from 0 to 56, with higher scores indicating more severe anxiety.
‖  A score of 1 on the Clinical Global Impression of Improvement (CGI-I) scale indicates that symptoms are very much improved, and a score 
of 2 indicates that symptoms are much improved; scores range from 1 to 7, with a score of 7 indicating that symptoms are very much worse.
Table 2. Primary and Secondary End Points Assessed at Day 15.*
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carried-forward method were similar to those of 
the primary analysis (Table S4 in the Supple-
mentary Appendix). At each time point from day 
2 through day 28, the unadjusted 95% confi-
dence intervals for the between-group difference 
in the change from baseline in HAM-D scores 
did not include zero, and the differences were 
generally in the same direction as those of the 
primary outcome, but the unadjusted 95% con-
fidence intervals for days 35 and 42 included 
zero (Table S5 and Fig. S3A in the Supplementary 
Appendix). At day 15, the percentage of patients 
who had a reduction of more than 50% from 
baseline in the HAM-D score was 79% in the 
SAGE-217 group and 41% in the placebo group 
(model-based odds ratio [analyzed with the use 
of a generalized estimating equation model], 9.6; 
95% CI unadjusted for multiplicity, 2.9 to 31.6); 
the percentage of patients with a HAM-D score 
of 7 or lower was 64% in the SAGE-217 group 
and 26% in the placebo group (model-based 
odds ratio, 5.3; unadjusted 95% CI, 2.1 to 13.3) 
(Fig. 2B and 2C and Table 2, and Table S5 in the 
Supplementary Appendix). At day 28, the percent-
age of patients who had a reduction of more 
than 50% from baseline in the HAM-D score 
was 62% in the SAGE-217 group and 46% in the 
placebo group, and the percentage of patients 
with a HAM-D score of 7 or lower was 52% and 
28%, respectively (Fig. S3B and S3C and Table S5 
in the Supplementary Appendix).
During the follow-up period, 3 patients in the 
SAGE-217 group and 11 patients in the placebo 
group were given concomitant antidepressants 
by investigators (Table S7 in the Supplementary 
Appendix). Patients and investigators remained 
unaware of the group assignments throughout 
the follow-up period. Results regarding the ef-
fects of SAGE-217 and placebo in patients who 
received and in patients who did not receive con-
comitant antidepressants are provided in Table 
S6 in the Supplementary Appendix.
Results for secondary end points are shown 
in Table 2. At day 15, the least-squares mean 
change from baseline in the Bech-6 score was 
−40.7±3.3 points in the SAGE-217 group and 
−25.7±3.4 points in the placebo group (least-
squares mean difference in change, −15.1 points; 
unadjusted 95% CI, −23.3 to −6.8). At day 15, the 
least-squares mean change from baseline in the 
MADRS score was −22.5±1.9 in the SAGE-217 
Figure 2. Efficacy End Points.
Scores on the 17-item Hamilton Depression Rating Scale (HAM-D) range 
from 0 to 52, with higher scores indicating more severe depression. The 
primary end point was the change in HAM-D score from baseline to day 15 
(Panel A). I bars indicate ±1 SE. The percentage of patients who had a re-
duction from baseline in HAM-D score of more than 50% (Panel B) and 
the percentage of patients who had a HAM-D score of 7 or lower (Panel C) 
were secondary end points.
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group and −15.0±1.9 in the placebo group (least-
squares mean difference in change, −7.6 points; 
unadjusted 95% CI, −12.3 to −2.8). At all time 
points, a higher percentage of patients in the 
SAGE-217 group than in the placebo group had 
a CGI-I score of 1 or 2, and the least-squares 
mean change from baseline in HAM-A score was 
greater in the SAGE-217 group than in the pla-
cebo group, but no inferences can be made be-
cause of the lack of adjustment for multiplicity 
in the analyses of secondary outcomes. (Addi-
tional data on secondary end points are provided 
in Figs. S4 through S6 and Tables S8 through 
S10 in the Supplementary Appendix.)
Safety
There were no serious adverse events and no 
deaths during this trial. The percentage of pa-
tients who had at least one adverse event during 
the treatment period was 53% in the SAGE-217 
group and 45% in the placebo group (Table 3). 
During days 21 through 42, a total of 4 addi-
tional adverse events in the SAGE-217 group and 
10 additional adverse events in the placebo group 
were reported (Table S11 in the Supplementary 
Appendix). Two patients in the SAGE-217 group 
discontinued the trial drug because they met a 
protocol criterion for discontinuation (one patient 
after day 6 because of nausea, dizziness, and 
headache, and the other patient after day 10 be-
cause of increased levels of alkaline phosphatase, 
alanine aminotransferase, aspartate aminotrans-
ferase, and γ-glutamyltransferase [this patient had 
mildly elevated baseline values and was asymp-
tomatic throughout the trial, and all values re-
turned to baseline or near-baseline levels after 
discontinuation of the trial medication]).
The most common adverse events that oc-
Variable
SAGE-217 Group 
(N = 45)
Placebo Group 
(N = 44)
Total 
(N = 89)
number (percent)
Patients with a serious adverse event† 0 0 0
Patients with a severe adverse event‡ 0 0 0
Patients with at least one adverse event 24 (53) 20 (45) 44 (49)
Adverse events reported in 3 or more patients
Headache 8 (18) 7 (16) 15 (17)
Dizziness 5 (11) 1 (2) 6 (7)
Nausea 5 (11) 1 (2) 6 (7)
Somnolence 3 (7) 1 (2) 4 (4)
Dry mouth 2 (4) 2 (5) 4 (4)
Sedation 2 (4) 2 (5) 4 (4)
Chromaturia 1 (2) 4 (9) 5 (6)
Decreased appetite 1 (2) 2 (5) 3 (3)
Insomnia 1 (2) 2 (5) 3 (3)
Pruritus 1 (2) 2 (5) 3 (3)
Diarrhea 0 3 (7) 3 (3)
Irritability 0 3 (7) 3 (3)
*  Adverse events during the treatment period are those that started or worsened from the time of the first dose of the trial 
intervention through 7 days after the last dose.
†  A serious adverse event was defined as any adverse event, occurring while the patient was receiving the trial medication 
or placebo, that resulted in death, was immediately life-threatening, led to inpatient hospitalization or prolongation of 
hospitalization, caused persistent or clinically significant disability or incapacity, or resulted in a congenital abnormality 
or birth defect.
‡  A severe adverse event was defined as any event that was incapacitating or caused an inability to perform normal activi-
ties of daily living.
Table 3. Adverse Events during the Treatment Period.*
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curred in at least 5% of patients in the SAGE-217 
group were headache, dizziness, nausea, and 
somnolence (Table 3). Subjective sleepiness, as 
assessed with the use of the Stanford Sleepiness 
Scale, was similar in the two groups. The score 
on the Stanford Sleepiness Scale was assessed 
before and after administration of SAGE-217 or 
placebo at multiple time points daily; data for 
days 1, 7, 14, and 15 are summarized in Table 
S12 in the Supplementary Appendix. In the 
SAGE-217 group, adverse events occurred in 67% 
of patients who received concomitant antidepres-
sants and in 48% of patients who received SAGE-
217 as monotherapy (Table S13 in the Supple-
mentary Appendix). Six patients in the SAGE-217 
group had dose reductions (from 30 mg to 20 mg) 
— five as the result of adverse events (dizziness 
[in two patients], somnolence [in one patient], 
sedation [in one patient], and nausea and vomit-
ing [in one patient]) and one because of patient-
reported sleepiness as assessed by the Stanford 
Sleepiness Scale. No patients in the placebo 
group had dose reductions.
Discussion
Among patients with moderate-to-severe major 
depressive disorder, treatment with SAGE-217 for 
14 days resulted in a reduction in depressive symp-
toms, as assessed on the basis of the change in 
the HAM-D score from baseline to day 15 and of 
changes in secondary end-point assessments that 
also were generally in the same direction as 
those of the primary outcome. The trial was not 
designed to confirm findings beyond the 15-day 
assessment period. One patient reported eupho-
ria as an adverse event, which suggests that in 
most patients the effect of SAGE-217 on allevia-
tion of depressive symptoms was not related to 
a temporary feeling of euphoria. The assessment 
of scores on the Bech-6 subscale showed im-
provement in all core symptoms of depression 
among patients who received SAGE-217. The ef-
fect of SAGE-217 was similar among patients who 
received adjunctive treatment with conventional 
antidepressants and those who received SAGE-217 
as monotherapy, although the number of pa-
tients in these groups was small, and the trial 
was not powered to assess this comparison. 
These findings may support a role for GABAA 
receptors in the pathophysiology of depres-
sion.4,38 On the basis of the pharmacologic prop-
erties of SAGE-217 as a positive allosteric modula-
tor of GABAA receptors, somnolence and sedation 
may be expected adverse events, and these were 
among the most common adverse events in the 
trial.
Limitations of the current trial include the 
small sample size, lack of adjustment for multi-
plicity in the testing of secondary end-point re-
sults, limited diversity in racial representation 
among the participants, and power to detect 
changes in depression severity only at day 15 
and not through the entire follow-up period. Data 
were missing for approximately 5% of patients 
in each group, but sensitivity analyses suggested 
that this did not alter the conclusions with re-
spect to the primary end point of the trial. The 
current trial did not include an active compara-
tor group, which limits comparison of the re-
sults with those of available antidepressants.
In conclusion, in this trial of SAGE-217, an oral, 
synthetic positive allosteric modulator of GABAA 
receptors, patients who received SAGE-217 had a 
greater reduction in depressive symptoms at day 
15 than patients who received placebo. Larger 
and longer trials are necessary to determine the 
durability and safety of SAGE-217 in the treat-
ment of depression.
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